Daraprim

After years of case-building, federal prosecutors will finally meet Martin Shkreli in court Monday, June 26, for a six-week trial. The former hedge-fund manager and pharmaceutical executive will face eight charges of securities and wire fraud, for which he has pleaded not guilty. “I’m...

Even under proverbial shackles, Martin Shkreli continues to flex his powerful muscles. The founder and former CEO of Turing Pharmaceuticals could reclaim corporate leadership ahead of the June 26 start to his securities fraud trial. The board of Turing met Wednesday and shareholders voted to elect...

Let’s talk Daraprim — again. The controversially pricey drug that set regulators on their toes and prompted critical evaluations of pharmaceutical practices nearly switched hands this week as Turing Pharmaceuticals considered a $100 million cash offer, according to Endpoints News....

Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) wants to stop egregious drug pricing issues, and Mallinckrodt PLC (NYSE: MNK) is its next target. Imprimis announced it will pursue a lower priced alternative to Mallinckrodt's HP Acthar Gel, which grossed sales of $1.3 billion in the prior year....

Pharmaceutical compounder Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) first stepped onto the national stage in December 2015, when the company announced its partnership with Express Scripts Holding Company (NASDAQ: ESRX) to distribute a $1 Daraprim alternative following Martin Shkreli and Turing...

While a company's financials may be one of the most important factors when it comes to making investment decisions, the person at the helm can make or break a firm's image in the public eye. This year, the private sector was full of scandals, crises and high-stakes decisions that cast the...

The most unpopular man in the pharmaceutical world is in a little bit of trouble. Turing Pharmaceuticals founder Martin Shkreli has been arrested on securities fraud related to a firm he founded, Bloomberg reported Thursday morning. Separately, Reuters citing witness said the entrepreneur...

The Washington Post, citing a Centers for Disease Control and Prevention study, reported the number of annual HIV diagnoses has dropped by 19 percent between 2005 and 2014. Men who have sex with other men accounted for around 67 percent of all HIV diagnoses in 2014. HIV cases among women fell by...

Martin Shkreli, CEO of Turing Pharmaceuticals, controversially raised the price of a potentially life-saving drug called Daraprim to $750 a pill from $13.50. Express Scripts Holding Company (NASDAQ: ESRX), the largest manager of prescription drug benefits, said on it will now cover a $1 a...

Martin Shkreli, CEO of Turing Pharmaceuticals, hosted a Reddit "Ask Me Anything." Shkreli became "the most hated man on the Internet" after he acquired a drug called Daraprim and raised its price to $750 a pill from $13.50. The top thread featured a discussion with a confirmed doctor who "schooled...

Investors are often fickle figures on Twitter. It doesn't help if these people are invested in a volatile, erratic space such as biotech. Couple that with a niche drug, Daraprim, that treats a very serious disease in Toxoplasmosis (via AIDS) and you have your makings of a public groundswell. After...

Hillary Clinton tweeted that "price gouging" in the specialty drug market is "outrageous." Terry Haines of Evercore ISI commented in a note that there is "almost no chance" of a president legislating drug pricing regulation. An appeal by Democratic candidate to "control" or "gauge" drug pricing...

A butterfly flaps its wings in China and a tsunami devastates Chile. In the biotech world, a finance-themed version of the butterfly effect is unfolding. As reported in the New York Times on Sunday, Turing Pharmaceuticals' Daraprim -- a drug used to treat toxoplasmosis -- saw its price...